NCT06085729View on ClinicalTrials.gov

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

September 2, 2027

Study Completion Date

December 31, 2027

Conditions
Prostate Cancer
Interventions
DRUG

ADI-PEG 20

Given by Injection

DRUG

Cabazitaxel

Given by IV (vein)

DRUG

Carboplatin

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER